Coenzyme Q10, Statin, and Spinocerebellar Ataxias (P6.047)

CONCLUSIONS:CoQ10 is associated with better clinical outcome in SCA1, 2, and 3 whereas statins are associated with worse clinical outcome in SCA6. These drug exposures did not appear to influence clinical progression within 2 years. CoQ10 and statins may have only symptomatic effects or require a longer period of time for disease modification.Study Supported by:American Brain Foundation Research Fellowship, Rare Disease Clinical Research Network RC1NS068897, and NINDS K08 NS083738.Disclosure: Dr. Kuo has nothing to disclose. Dr. Lo has nothing to disclose. Dr. Figueroa has nothing to disclose. Dr. Pulst has received personal compensation for activities with Athena Diagnostics. Dr. Pulst has received license or royalty payments from Cedars-Sinai Medical Center. Dr. Perlman has received research support from Santhera Pharmaceuticals. Dr. Wilmot has nothing to disclose. Dr. Gomez has nothing to disclose. Dr. Schmahmann has received license fee payments from Massachusetts General Hospital. Dr. Paulson has received personal compensation for activities with Shire Human Genetic Therapy. Dr. Paulson has received license fee payments from Sirna Therapeutics. Dr. Paulson has received research support from Shire Human Genetic Therapy. Dr. Shakkottai has nothing to disclose. Dr. Ying has nothing to disclose. Dr. Zesiewicz has received personal compensation for activities with Teva Neuroscience, GE Healthcare, Pro Ce, UCB Pharma, and Friedreich's Ataxia Research Alliance. Dr. Zesiewicz ha...

Source: Neurology - April 9, 2014 Category: Neurology Authors: Kuo, S.-H., Lo, R., Figueroa, K., Pulst, S., Perlman, S., Wilmot, G., Gomez, C., Schmahmann, J., Paulson, H., Shakkottai, V., Ying, S., Zesiewicz, T., Bushara, K., Geschwind, M., Xia, G., Subramony, S., Ashizawa, T. Tags: Movement Disorders: Spinocerebellar Ataxias Source Type: research